PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
PolyPid Ltd. announced new pharmacokinetic data from its Phase 3 SHIELD II trial for D-PLEX100, showing sustained local doxycycline release up to 32 days with minimal systemic exposure. These results highlight D-PLEX100's potential to significantly reduce surgical site infections (SSIs), supported by a recent 60% relative risk reduction in SSI inci…